Chronic Inflammation: Causes, Biomarkers, and Evidence-Based Reduction

1. Acute vs. Chronic Inflammation: The Biology of a Switch That Fails to Turn Off

Acute inflammation is one of the most elegant processes in biology. When a pathogen is detected or tissue is damaged, pattern recognition receptors — primarily Toll-like receptors (TLRs) on macrophages and dendritic cells — activate the transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells). NF-κB translocates to the nucleus within minutes and switches on genes encoding pro-inflammatory cytokines: interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumour necrosis factor alpha (TNF-α). These cytokines orchestrate the cardinal signs of inflammation — vasodilation, increased vascular permeability, neutrophil recruitment — that ultimately clear the threat. IL-6 simultaneously signals the liver to produce C-reactive protein (CRP) and other acute-phase proteins within 6–12 hours, a biochemical alarm system visible in a standard blood test.

The critical distinction is resolution. Acute inflammation is self-limiting: lipid mediators called resolvins and protectins (derived from EPA and DHA) actively terminate the cytokine cascade, and regulatory T cells dampen immune activation once the threat is cleared. In chronic inflammation, this resolution programme fails or is overwhelmed. The NF-κB pathway remains partially activated by a sustained low-level signal — whether from gut-derived lipopolysaccharide (LPS), visceral adipose tissue secreting adipokines, or oxidised LDL particles — keeping circulating IL-6, IL-1β, and TNF-α chronically elevated at 2–3× above normal. The cytokine cascade does not produce a dramatic acute response but instead applies constant, low-grade pressure on every major organ system over years and decades.

What makes chronic inflammation so dangerous is precisely its subclinical nature. There are rarely symptoms. A person can carry an hsCRP of 4–6 mg/L — indicating high-grade inflammatory activity — and feel entirely normal. Yet at this level, meta-analyses show a 2-fold increase in cardiovascular event risk, a 30% increase in all-cause cancer risk, and measurable acceleration of epigenetic ageing. The CANTOS trial (2017, NEJM, n=10,061) demonstrated this causal relationship conclusively: neutralising IL-1β with the monoclonal antibody canakinumab reduced cardiovascular events by 15% independent of lipid lowering, confirming inflammation as an independent causal mechanism rather than merely a marker.

2. Inflammaging: Why Inflammation Rises With Age

The term “inflammaging” — coined by immunologist Claudio Franceschi in 2000 — describes the sterile, chronic, low-grade inflammatory state that is a hallmark of biological ageing. Circulating IL-6 levels increase 2–4-fold between age 20 and 80 even in healthy individuals. IL-6 above 2.0 pg/mL in older adults predicts disability, frailty, cognitive decline, and all-cause mortality more powerfully than almost any other single biomarker. The mechanism is multifactorial. First, the immune system accumulates exhausted and senescent immune cells — particularly senescent T cells expressing the marker p16INK4a — that are stuck in a pro-inflammatory state and cannot be cleared by normal apoptosis. Second, accumulated senescent non-immune cells (fibroblasts, endothelial cells, adipocytes) secrete what is termed the Senescence-Associated Secretory Phenotype (SASP).

The SASP is a cocktail of pro-inflammatory cytokines, matrix metalloproteinases, and growth factors — including IL-6, IL-8, MCP-1, and TNF-α — secreted constitutively by senescent cells. Senescent cells accumulate exponentially with age because the immune system (via “immune senescence”) progressively loses its ability to clear them. A single senescent cell can spread inflammatory signals to dozens of neighbouring cells through paracrine SASP secretion, a phenomenon called the “bystander effect.” By age 70, senescent cells may represent 15–20% of certain tissue compartments. Critically, SASP-derived inflammation is self-reinforcing: NF-κB activation in surrounding cells can itself induce further senescence, creating feedforward inflammatory loops that accelerate tissue ageing. Rapamycin and senolytics such as dasatinib + quercetin are currently being studied in clinical trials for their ability to clear senescent cells and reduce SASP-driven inflammaging.

The downstream consequences of inflammaging connect to virtually every major age-related disease. In the cardiovascular system, chronic IL-6 signalling promotes arterial smooth muscle cell migration and atherosclerotic plaque instability. In the brain, SASP-driven neuroinflammation activates microglia and impairs the amyloid clearance mechanisms disrupted in Alzheimer’s disease — a 2023 meta-analysis in Nature Aging confirmed hsCRP as an independent predictor of dementia risk (HR 1.37 per doubling of CRP). In muscle, chronic TNF-α signalling activates FOXO transcription factors, promoting protein catabolism and contributing to sarcopenia. In adipose tissue, macrophage infiltration driven by MCP-1 creates insulin resistance. Inflammaging is not an inevitable consequence of chronological ageing — it is a targetable, measurable biological process, and individuals with the lowest inflammatory burden at 65 have health trajectories resembling those 10–15 years younger.

3. Inflammation Biomarkers: What to Test and What the Numbers Mean

High-sensitivity CRP (hsCRP) is the most widely validated inflammatory biomarker for cardiovascular risk stratification. Standard CRP assays detect values above 10 mg/L (acute infection/injury range); hsCRP reliably detects 0.1–10 mg/L, the range relevant to chronic inflammatory disease. The American Heart Association risk stratification places low risk at <1 mg/L, average at 1–3 mg/L, and high at >3 mg/L. An optimal target in a longevity context is below 0.5 mg/L. Importantly, hsCRP is a downstream marker synthesised by the liver in response to IL-6 stimulation — it has a half-life of 19 hours, making it relatively stable for sampling but slower to respond to interventions than upstream cytokines. A single hsCRP measurement can be confounded by acute illness; two measurements 2–4 weeks apart are required for clinical decisions.

IL-6 (reference: <3.0 pg/mL) is arguably the more clinically important biomarker because it sits further upstream in the inflammatory cascade and has direct effects on metabolic health beyond CRP production — it drives hepatic gluconeogenesis, bone resorption, and haematopoietic changes. IL-6 above 3.0 pg/mL is associated with a 2.4-fold increase in all-cause mortality risk in older adults (Harris et al., Journal of the American Geriatrics Society). Fibrinogen (reference: 2.0–4.0 g/L) is both a coagulation protein and an acute-phase reactant — chronically elevated fibrinogen (>4.5 g/L) indicates systemic inflammation and raises thrombotic risk independently of LDL. Homocysteine (<10 µmol/L optimal) activates NF-κB in endothelial cells and is elevated by B-vitamin deficiency; hyperhomocysteinaemia (>15 µmol/L) is a strong independent cardiovascular risk marker responsive to folate, B6, and B12 supplementation.

Ferritin (optimal: 50–150 ng/mL in men, 30–100 ng/mL in women) is both an iron storage protein and a major acute-phase reactant. Elevated ferritin (>200–300 ng/mL) can indicate either iron overload (associated with oxidative stress and inflammation) or systemic inflammatory activation unrelated to iron stores — distinguishing the two requires transferrin saturation and serum iron. The omega-3 index (EPA + DHA as % of red blood cell fatty acids; optimal >8%) is not conventionally classified as an inflammatory biomarker but is arguably the most actionable — it directly reflects the substrate balance between pro-inflammatory arachidonic acid-derived eicosanoids and anti-inflammatory EPA/DHA-derived resolvins. A 2018 analysis of NHANES data found that over 95% of US adults have an omega-3 index below 8%, placing the majority of the population in a pro-inflammatory fatty acid environment. These six biomarkers together constitute a comprehensive inflammatory risk profile.

4. Diet and Inflammation: The Mediterranean Model, Ultra-Processed Foods, and the Seed Oil Debate

The Mediterranean dietary pattern has the most robust randomised controlled trial evidence for reducing inflammatory biomarkers of any dietary intervention studied to date. The PREDIMED trial (2013, NEJM, n=7,447) randomised high-risk individuals to a Mediterranean diet supplemented with extra-virgin olive oil (EVOO) or nuts versus a low-fat control diet. The Mediterranean arms reduced cardiovascular events by 30% and showed significant reductions in hsCRP, IL-6, and vascular cell adhesion molecule-1 (VCAM-1) versus control. The anti-inflammatory mechanisms include: polyphenols in EVOO (primarily oleocanthal, which inhibits COX-1 and COX-2 similarly to ibuprofen), high mono- and polyunsaturated fatty acids that reduce pro-inflammatory ceramide synthesis, abundant dietary fibre feeding anti-inflammatory short-chain fatty acid (SCFA)-producing gut bacteria, and the high omega-3:omega-6 ratio provided by oily fish, walnuts, and flaxseed.

Ultra-processed foods (UPFs) — defined by the NOVA classification as industrially formulated products containing additives not used in home cooking (emulsifiers, flavour enhancers, stabilisers) — are the primary pro-inflammatory driver in modern diets. The Hall et al. crossover RCT (Cell Metabolism, 2019) provided mechanistic insight: participants on a matched-calorie UPF diet consumed 500 kcal/day more due to impaired satiety signalling and showed elevated markers of intestinal permeability, suggesting barrier disruption as a direct mechanism. Emulsifiers including carboxymethylcellulose (CMC) and polysorbate-80 have been shown in mouse models by Chassaing et al. (Nature, 2015) to disrupt the gut mucus layer, promote bacterial translocation, and trigger low-grade colitis via TLR5 signalling. A 2023 prospective cohort study in eClinicalMedicine (n=22,895) found every 10% increase in UPF consumption associated with a 12% increase in cardiovascular risk, partially mediated by inflammatory biomarkers.

The seed oil debate deserves a nuanced evidence-based assessment. Industrial seed oils (soybean, corn, sunflower, cottonseed) are the primary source of linoleic acid (LA, 18:2 omega-6) in modern Western diets, which has increased from ~2% to ~8% of total energy intake since 1900. LA is converted to arachidonic acid (AA, 20:4 omega-6), the precursor to pro-inflammatory prostaglandins (PGE2), leukotrienes (LTB4), and thromboxane A2. However, the evidence that LA per se is pro-inflammatory in humans is mixed: several RCTs substituting saturated fat with linoleic acid showed reduced CRP. The more compelling mechanistic concern is the LA:omega-3 competitive ratio — when dietary omega-6 exceeds omega-3 by 15:1 or more (common in Western diets), it starves the eicosanoid pathway of EPA and DHA, the precursors to anti-inflammatory resolvins and protectins. Fructose presents a more direct and mechanistically cleaner case: high-fructose corn syrup drives hepatic de novo lipogenesis, raises uric acid levels (which activates the NLRP3 inflammasome, releasing IL-1β), and promotes leptin resistance, creating a chronic inflammatory microenvironment independent of caloric excess.

5. Lifestyle Drivers: Sleep, Sedentary Behaviour, and Chronic Stress

Sleep is one of the most potent anti-inflammatory physiological processes in the human body, and its disruption is one of the most consistent inducers of inflammatory activation. The mechanism is rapid and direct: a 2013 study by Irwin et al. published in Sleep demonstrated that restricting healthy adults to 4 hours of sleep for a single night was sufficient to activate monocytic NF-κB signalling, with significant elevations in IL-6 and TNF-α detectable in peripheral blood the following morning. The reason lies in the hormonal architecture of sleep: slow-wave sleep (SWS) suppresses sympathetic nervous system activity and reduces circulating cortisol, creating a window of immune regulation. During SWS, the glymphatic system clears neuroinflammatory metabolites — including tau oligomers and amyloid-beta — that accumulate during waking hours. Fragmented or insufficient sleep impairs both SNS withdrawal and glymphatic clearance simultaneously, compounding neuroinflammatory burden.

Sedentary behaviour is an independent inflammatory driver, distinct from the benefits of exercise. Prolonged sitting activates lipoprotein lipase suppression in skeletal muscle, reducing triglyceride clearance and elevating circulating lipid intermediates that stimulate TLR4-mediated NF-κB activation. A 2012 meta-analysis in Diabetologia (Biswas et al.) found that sitting time was associated with inflammatory markers even after adjusting for moderate-to-vigorous physical activity — meaning exercise cannot fully offset 8+ hours of daily sitting. In contrast, even light ambulatory activity (standing, walking at <3 METs) significantly attenuates these inflammatory signals. The underlying mechanism involves continuous low-amplitude muscle contractions producing anti-inflammatory myokines — particularly IL-15 and irisin — that suppress adipose tissue inflammation. The practical implication is that breaking sitting with 2 minutes of standing or walking every 30 minutes produces measurable inflammatory benefit independent of formal exercise.

Psychological stress activates the HPA axis, releasing cortisol, which acutely suppresses inflammation. Paradoxically, chronic psychological stress produces the opposite effect: sustained cortisol exposure causes glucocorticoid receptor (GR) resistance in immune cells, particularly monocytes and lymphocytes. When GRs desensitise, the normal cortisol-mediated anti-inflammatory brake on NF-κB is lost, and immune cells become hyperresponsive to pro-inflammatory stimuli. This phenomenon — termed glucocorticoid resistance — was documented in Cohen et al. (PNAS, 2012), where participants with a history of stressful life events showed significantly higher IL-6 production from stimulated monocytes compared to controls, regardless of current cortisol levels. The vagal anti-inflammatory pathway offers a counterweight: activation of the vagus nerve releases acetylcholine that binds α7-nicotinic receptors on macrophages, directly inhibiting TNF-α and IL-1β synthesis. Practices that increase vagal tone — slow diaphragmatic breathing, cold water exposure, regular aerobic exercise — therefore reduce inflammation through a cholinergic mechanism independent of HPA axis modulation.

6. Environmental Sources: Gut Dysbiosis, Air Pollution, and Mycotoxins

Metabolic endotoxemia — the chronic elevation of circulating bacterial lipopolysaccharide (LPS) derived from gram-negative gut bacteria — is one of the most important yet underappreciated drivers of chronic inflammation discovered in the past two decades. Patrice Cani and colleagues first characterised metabolic endotoxemia in 2007 (Diabetes), showing that high-fat diet in mice raised plasma LPS 2–3-fold, activating hepatic TLR4 signalling and producing liver and adipose tissue inflammation. LPS translocates across a permeable intestinal epithelium — the “leaky gut” — and is transported to the liver via chylomicrons. Even sub-nanogram per millilitre concentrations of LPS are sufficient to activate TLR4 on macrophages and Kupffer cells, triggering NF-κB and IL-1β release. Human data consistently show that plasma LPS-binding protein (LBP), a surrogate for LPS exposure, correlates with metabolic syndrome, insulin resistance, and cardiovascular risk independently of conventional risk factors. Butyrate-producing bacteria (Faecalibacterium prausnitzii, Akkermansia muciniphila) maintain epithelial barrier integrity — their depletion, common in antibiotic users and those with low-fibre diets, is a direct upstream cause of elevated endotoxin permeation.

Airborne particulate matter — especially PM2.5 (fine particles <2.5 µm in aerodynamic diameter from combustion sources) — is the environmental toxin with the best-documented inflammatory effect in human populations. PM2.5 particles penetrate to the pulmonary alveoli and, via free radical-generating quinones and metals on their surface, activate NF-κB in lung macrophages and epithelial cells within hours of exposure. This produces both local pulmonary inflammation and systemic spillover: a 2020 analysis of 652 cities (Burnett et al., NEJM) found a linear dose-response between ambient PM2.5 and cardiovascular mortality with no observable threshold. Long-term PM2.5 exposure at levels above the WHO guideline of 5 µg/m³ (the annual mean; most urban environments exceed 10–25 µg/m³) is associated with 6–13% increases in all-cause mortality per 10 µg/m³ increment. PM2.5 also oxidises LDL particles, accelerating atherosclerotic plaque formation independently of serum LDL levels, a mechanism confirmed by Araujo et al. in studies of concentrated ambient particle exposure in apoE-knockout mice (Circulation Research, 2008).

Mycotoxins — secondary fungal metabolites produced by Aspergillus, Fusarium, Stachybotrys, and Penicillium species — represent a less appreciated but clinically significant environmental inflammatory trigger. Ochratoxin A activates NF-κB in kidney cells and suppresses T-regulatory cell function, promoting autoimmune-type inflammatory responses. Aflatoxin B1 (classified Group 1 carcinogen by the IARC) generates reactive oxygen species via cytochrome P450 activation that oxidise DNA and activate inflammatory signalling. Water-damaged buildings are the primary indoor mycotoxin source: trichothecene mycotoxins from Stachybotrys chartarum (black mould) inhibit protein synthesis in immune cells and can induce systemic inflammation and cytokine dysregulation in occupants — a condition sometimes termed CIRS (chronic inflammatory response syndrome). Clinically, suspected mycotoxin exposure should be evaluated with urinary mycotoxin testing (OAT or ELISA-based), nasal endoscopy for fungal sinusitis, and visual contrast sensitivity testing (VCS), the latter validated by Shoemaker et al. as a functional neurological marker for biotoxin-related neuroinflammation.

7. Evidence-Based Interventions: Omega-3s, Curcumin, Resveratrol, and Exercise Timing

Omega-3 fatty acids (EPA and DHA) have the strongest and most consistent evidence base of any nutritional intervention for reducing inflammatory biomarkers. EPA competes directly with arachidonic acid (AA) for phospholipase A2 and cyclooxygenase-2 (COX-2), reducing prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) production by 30–50% in favour of less pro-inflammatory EPA-derived Series-3 eicosanoids. Beyond eicosanoid competition, EPA and DHA are converted to specialised pro-resolving mediators (SPMs) — resolvins (RvE1, RvE2 from EPA; RvD1-6 from DHA), protectins (PD1/neuroprotectin D1), and maresins (MaR1, MaR2 from DHA) — that actively terminate inflammatory responses rather than merely suppressing them. A 2012 meta-analysis across 26 RCTs (Calder, PLOS ONE) confirmed significant reductions in TNF-α (−0.81 pg/mL, 95% CI −1.24 to −0.38) and IL-6 (−0.49 pg/mL, 95% CI −0.79 to −0.19) with ≥2 g/day EPA+DHA. Effective clinical doses are 2–4 g/day EPA+DHA from triglyceride-form fish oil; the omega-3 index should be monitored to confirm target achievement (>8%).

Curcumin — the principal polyphenol of turmeric (Curcuma longa) — has potent in vitro NF-κB inhibitory activity and has generated enormous clinical interest, but its translation to clinical use is complicated by severe bioavailability limitations. Curcumin from standard turmeric powder is absorbed at <1% in most formulations and is rapidly conjugated and eliminated. This explains why earlier RCTs using 1–2 g/day standard curcumin showed inconsistent results. Enhanced formulations have dramatically changed the picture: Theracurmin (colloidal dispersion) shows 27-fold higher bioavailability, CURCUWIN (curcumin-phospholipid complex) shows 136-fold enhancement versus standard curcumin in comparative pharmacokinetic studies, and Longvida (SLCP, solid lipid curcumin particles) shows superior CNS penetration. With high-bioavailability formulations, clinical RCTs have demonstrated significant reductions in CRP (−0.45 mg/L, 95% CI −0.78 to −0.12) and IL-6 in meta-analysis (Tabrizi et al., Phytotherapy Research, 2019). The mechanistic target beyond NF-κB includes inhibition of the NLRP3 inflammasome and upregulation of Nrf2-driven antioxidant gene expression.

Exercise timing relative to meals significantly modulates the inflammatory response to physical activity. Exercise performed in a fasted state or before the first meal of the day potentiates AMPK activation and PGC-1α-driven mitochondrial biogenesis, both of which suppress NF-κB and reduce basal inflammatory tone. Aerobic exercise at 60–70% VO2max for ≥30 minutes acutely elevates IL-6 from contracting skeletal muscle — but this muscle-derived IL-6 is metabolic (not inflammatory) and triggers anti-inflammatory IL-10 and IL-1 receptor antagonist (IL-1Ra) release, ultimately reducing systemic inflammation. A 2017 meta-analysis across 35 RCTs (Fedewa et al., Sports Medicine) confirmed that chronic aerobic training reduces hsCRP by a mean of 0.31 mg/L, with effect sizes largest in individuals with elevated baseline CRP (>3 mg/L). Resistance training produces comparable inflammatory reductions via different pathways — muscle mass expansion increases insulin-sensitising irisin secretion and reduces visceral adipose tissue, one of the most prolific sources of chronic IL-6 and MCP-1 production. High-intensity interval training (HIIT) amplifies these effects but may temporarily elevate inflammatory markers in the 24–48 hours post-session; consistent recovery and sleep are required to capture the net anti-inflammatory benefit.

8. Pharmaceutical Anti-Inflammatory Approaches: Metformin, Low-Dose Aspirin, and Statins

Metformin, the first-line pharmacological treatment for type 2 diabetes, has substantial evidence for anti-inflammatory effects that are at least partially independent of its glucose-lowering mechanism. Metformin activates AMPK (AMP-activated protein kinase) — the master metabolic energy sensor — which directly phosphorylates and inhibits IKKβ, the kinase required for IκB degradation and NF-κB nuclear translocation. It also inhibits mitochondrial complex I, reducing mitochondrial reactive oxygen species (mtROS) production, one of the key upstream signals for NLRP3 inflammasome activation. Clinical data consistently show metformin reduces hsCRP by 10–20% and IL-6 by 15–25% in both diabetic and non-diabetic populations. The TAME (Targeting Ageing with Metformin) trial, currently ongoing at multiple US academic centres (n=3,000, ages 65–79), is specifically testing whether these pleiotropic anti-inflammatory effects translate to delayed onset of age-related comorbidities, including cardiovascular disease, cancer, and dementia — a landmark trial that would validate the inflammaging hypothesis in a prospective, randomised design.

Low-dose aspirin (75–100 mg/day) irreversibly acetylates COX-1 and COX-2, reducing thromboxane A2-mediated platelet aggregation and PGE2-mediated inflammatory signalling. For primary prevention, the benefit-risk calculation has shifted significantly since the 2018 ASPREE trial (NEJM, n=19,114, healthy adults >70 years) showed that low-dose aspirin increased major bleeding events without reducing cardiovascular mortality or cancer — reversing decades of prescribing practice. However, in secondary prevention for established cardiovascular disease, low-dose aspirin remains a cornerstone therapy with a clear net benefit. Emerging research suggests aspirin may also have anti-cancer effects through prostaglandin-mediated immune evasion mechanisms: a 2022 analysis in The Lancet (CAPP2 trial) found aspirin reduced colorectal cancer incidence by 50% in Lynch syndrome carriers, a finding replicated across multiple cohort studies. The current evidence supports low-dose aspirin only in individuals with established CVD, or very high calculated cardiovascular risk (>20% 10-year ASCVD score), where benefits clearly outweigh bleeding risk.

Statins (HMG-CoA reductase inhibitors) are among the most studied pharmaceutical agents in history, and their cardiovascular benefits extend substantially beyond LDL-cholesterol reduction via pleiotropic anti-inflammatory mechanisms. Statins reduce isoprenylation of Rho GTPases — signalling molecules that activate NF-κB and ROCK (Rho-associated protein kinase) — independently of cholesterol synthesis inhibition. This explains why statins reduce hsCRP by 20–40% even when LDL is well-controlled, and why high-sensitivity CRP is a key co-determinant of statin benefit. The JUPITER trial (NEJM, 2008, n=17,802) enrolled individuals with normal LDL but elevated hsCRP (>2 mg/L) and found rosuvastatin 20 mg reduced major cardiovascular events by 44% and all-cause mortality by 20%, demonstrating that anti-inflammatory efficacy contributes substantially to statin benefits. IL-6 receptor antagonists (tocilizumab) and anti-IL-1β therapy (canakinumab, anakinra) represent the frontier of inflammation-targeted pharmaceutical therapy, currently FDA-approved for specific inflammatory diseases with ongoing trials for broader cardiovascular and oncological indications.

Frequently Asked Questions